SKB 500
Alternative Names: SKB-500Latest Information Update: 16 Jan 2025
Price :
$50 *
At a glance
- Originator Sichuan Kelun-Biotech Biopharmaceutical
- Developer Sichuan Kelun Pharmaceutical Research Institute
- Class Antibacterials; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 24 Dec 2024 NMPA approves clinical trial application for SKB 500 in Solid tumours (Sichuan Kelun Biotech pipeline, December 2024)
- 13 Dec 2024 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease) in China (IV) (NCT06736327)